Class Action Lawsuit Notification for Actinium Pharmaceuticals
Investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) should take note of an important announcement regarding a class action securities lawsuit. Levi & Korsinsky LLP, a reputable law firm, has reached out to inform shareholders about this significant legal development.
Details of the Class Action Lawsuit
This lawsuit is aimed at recovering losses for those who have invested in Actinium. Allegations suggest that the company's actions between October 31, 2022, and August 2, 2024, may have involved securities fraud. This announcement acts as a reminder for investors to stay informed about their rights and possible recourse available through this legal channel.
Investors Impacted by Allegations
According to the filed complaint, vital information was allegedly withheld from investors. This includes claims that the Company's Phase 3 Sierra trial data may not have met FDA standards necessary for approval of the targeted radiotherapy, Iomab-B BLA. Furthermore, it is claimed that additional analyses provided to the FDA, which aimed to lessen concerns around the trial's unsatisfactory overall survival data, were not likely to meet regulatory expectations.
What Should Affected Investors Do?
If you believe you have experienced a loss due to this situation, it is crucial to know that you have until May 27, 2025, to act. Investors can request to be appointed as lead plaintiff while remaining eligible for any recovery without requiring this official appointment.
Cost-Free Participation
Levi & Korsinsky emphasizes that participation in this class action comes at no cost to individuals involved. This means no out-of-pocket expenses or fees will be necessary to engage in the lawsuit.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has a solid track record spanning over two decades, having recovered substantial amounts of money for investors impacted by securities fraud. The firm prides itself on its extensive experience in handling complicated securities litigation and is well-equipped with over 70 skilled professionals dedicated to supporting investor rights.
Contact Information
For further inquiries, investors can reach out to: Levi & Korsinsky, LLP. Joseph E. Levi, Esq. and Ed Korsinsky, Esq. are available to assist. The office is located at 33 Whitehall Street, 17th Floor, New York, NY 10004. You can contact them by phone at (212) 363-7500 or find more information on their website.
Frequently Asked Questions
What is a class action lawsuit?
A class action lawsuit allows a group of investors to unite and bring a collective case against a Defendant, claiming similar grievances.
Who can participate in this class action suit?
Anyone who suffered financial losses as a result of the alleged actions of Actinium Pharmaceuticals, Inc. during the specified period can participate.
What are the risks of joining a class action lawsuit?
There are generally minimal risks in joining a class action, as there are no upfront costs, making it a feasible option for affected investors.
How is compensation determined in a class action lawsuit?
Compensation is typically distributed based on the extent of losses suffered by each participant during the relevant timeframe.
What happens next after joining?
Once you express your interest, you will be kept informed of the case's developments while remaining eligible for compensation if a settlement is reached.
